Biovail NDA For New Wellbutrin Formulation Is “Not Approvable”
FDA had concerns over design of pharmacokinetic studies of once-daily salt formulation of bupropion for depression, the firm says.
FDA had concerns over design of pharmacokinetic studies of once-daily salt formulation of bupropion for depression, the firm says.